340B Regulatory Changes: Impact and Best Practices for Manufacturers
by Apexus, the 340B Prime Vendor | May 7, 2019
Section 340B of the Public Health Service (PHS) Act requires drug manufacturers participating in the Medicaid Drug Rebate Program (MDRP) to sign a pharmaceutical pricing agreement (PPA) with the Secretary of Health and Human Services (HHS) to offer covered outpatient drugs at or below statutory ceiling prices to certain covered entities. The 340B Drug Pricing Program (340B Program) is administered by the Health Resources & Services Administration (HRSA).
340B By The Numbers
HRSA establishes program policy for manufacturers and covered entities. On January 5, 2017, HRSA issued the 340B Ceiling Price and Civil Monetary Penalties Final Rule (340B CMP Final Rule), which became effective January 1, 2019. The 340B CMP Final Rule includes key requirements for manufacturers and establishes CMPs for manufacturers that knowingly and intentionally overcharge covered entities.
In accordance with the section 340B of the PHS Act, HRSA is required to collect information from manufacturers to verify the accuracy of 340B ceiling prices, and then make ceiling prices available to covered entities. To this end, HRSA developed the new secure pricing component of the Office of Pharmacy Affairs Information System (OPAIS), which provides covered entity and manufacturer authorized users with access to 340B ceiling prices.
The purpose of this paper, prepared by Apexus, the 340B Prime Vendor, is to provide an overview of the CMP Final Rule and the pricing component of the 340B OPAIS. In addition, we share best practices on how to achieve compliance and operational efficiencies.
What is the HRSA 340B Prime Vendor?
Apexus serves as the Prime Vendor for the 340B Drug Pricing Program. As the 340B Prime Vendor, Apexus manages program distribution and serves as a partner to all 340B stakeholders in improving the 340B Program’s overall integrity. The Prime Vendor also provides education and compliance tools to 340B stakeholders. Additional information about the Prime Vendor Program is available at 340Bpvp.com.
Key Regulatory Changes: 340B Ceiling Price Calculation and Civil Monetary Penalties Final Rule
340B Ceiling Price Calculation
Overview: The 340B CMP Final Rule explains that the 340B ceiling price for a covered outpatient drug is equal to the average manufacturer price (AMP) from the preceding calendar quarter for the smallest unit of measure minus the unit rebate amount (URA), and will be calculated using six decimal places. The CMP Final Rule established that the ceiling price will be rounded to two decimal places and will be published in the 340B OPAIS on a quarterly basis. A 340B ceiling price that equals or rounds to zero will be published in the 340B OPAIS as $0.01 and the manufacturer must charge covered entities $0.01 per unit of measure.
For new drugs, an AMP may not be available until the fourth quarter that the drug is available for sale. However, the CMP Final Rule requires manufacturers to estimate and make available the 340B ceiling price for a new covered outpatient drug as of the date the drug is first available for sale. For the purpose of submitting new drug price data in the 340B OPAIS, the calculated estimate is wholesale acquisition cost (WAC) minus the appropriate rebate percentage until AMP is available, which is no later than the fourth quarter that the new drug is available for sale. This new drug price estimation in the 340B CMP Final Rule is to ensure that manufacturers have a standard method for estimating the 340B ceiling price of a new covered outpatient drug to ensure that covered entities receive the 340B ceiling price on their purchases.
In addition, for new drugs, manufacturers are required to calculate the actual 340B ceiling price and offer to refund or credit the covered entity the difference between the estimated 340B ceiling price (WAC minus URA) and the actual 340B ceiling price within 120 days of the determination by the manufacturer that an overcharge occurred. An instance of overcharging may occur either at the time of initial purchase or when subsequent ceiling price recalculations, due to pricing data submitted to Centers for Medicare & Medicaid Services (CMS) or new drug price estimates, result in a covered entity paying more than the ceiling price.
For more information, please review the 340B CMP Final Rule (82 FR 1210, January 5, 2017).
- Establish internal procedures that follow the new drug pricing methodology (WAC minus URA) when establishing the initial 340B ceiling price. Note that this may differ from a manufacturer’s current ceiling price estimation methodologies and will be the 340B price published by HRSA in the pricing component of the 340B OPAIS.
- Information in the Medicaid Drug Data Reporting System (DDR) should be updated to avoid price discrepancies. If a manufacturer provides HRSA different data than what is in the DDR, manufacturers will be required to reconcile and update the information accordingly.
- Be aware that the 340B ceiling price is first calculated to the sixth decimal place, and the ceiling price offered to covered entities is rounded to two decimal places when published. Please visit HRSA’s website for more information on the required data elements in 340B OPAIS and information on rounding rules.
Civil Monetary Penalties
Overview: HRSA has the authority to impose civil monetary penalties on manufacturers that “knowingly and intentionally” overcharge a 340B covered entity more than the 340B ceiling price. These penalties would be in addition to refunds of overcharges to covered entities.
HRSA states that instances of overcharging may occur at the time of the original sale or when recalculations of the 340B drug price occur. The HHS Office of Inspector General (OIG) has delegated authority to impose CMPs and to interpret the meaning of “knowingly and intentionally” on a case-by-case basis using the definitions, standards, and procedures under the federal regulation.
- Ensure appropriate staff from required departments are educated about the 340B CMP Final Rule and potential impact. Review the regulation here. HRSA expects covered entities and manufacturers to work in good faith to resolve any overpayments in accordance with standard business practices. If a manufacturer determines that it has charged covered entities more than the 340B ceiling price, manufacturers should notify HRSA of their intention to issue a refund. The 340B Prime Vendor has a voluntary program to help manufacturers refund money primarily through a distributor credit to the covered entity’s 340B wholesaler account.
- Develop business rules and standard procedures for offering refunds to covered entities in the case of overcharges. Solicit internal cross-functional expertise from areas such as government pricing, contract operations, compliance, public policy, and legal. When necessary, solicit support from external stakeholders. Although the 340B CMP Final Rule addresses a timeframe for repayment on overcharges related to new drugs, HRSA expects repayment (refunds) to be made on all overcharges to covered entities.
- Have an efficient plan to process refunds. Consider potential costs such as due diligence calls, returned mail and/or checks leading to subsequent mailings, and tax requirements of obtaining W-9 forms from covered entities.
- Gain awareness of resources available to assist with compliance. Refer to the HRSA 340B Program website to ensure compliance and locate resources such as Manufacturer Notices to Covered Entities and Manufacturer Resources, including FAQs. The Prime Vendor also has resources available to assist with compliance.
- Monitor 340B pricing offered by your distributor network. Manufacturers are held liable even when the cause of an overcharge was a wholesaler error. Because manufacturers are responsible for setting appropriate 340B ceiling prices, they are responsible for the conduct of business partners with whom they contract.
Operational Changes: OPAIS Pricing System
Overview: The 340B OPAIS pricing component captures pricing data from manufacturers and CMS and then calculates and verifies 340B ceiling prices through a quarterly process. This will increase the integrity and effectiveness of 340B information from participating manufacturers. Manufacturers made their initial submissions of 340B pricing data to the secure pricing component of OPAIS during the first quarter of 2019, and 340B ceiling prices were available to covered entities on April 1, 2019.
In addition to the best practices listed here, manufacturers’ authorized users should refer to the 340B Office of Pharmacy Affairs Information System (OPAIS) Pricing Component User Guide for Manufacturer Authorizing Officials and Primary Contacts.
- Ensure that your Authorizing Official (AO) and Primary Contacts (PCs) are current and up to date for each labeler code, and that authorized user information is updated in a timely manner when internal responsibilities change. This is an expectation from HRSA. The manufacturer’s AO and PC have responsibility for providing quarterly pricing data for each labeler code, either manually or via text file upload. The AO and PC access their respective accounts using their email addresses and following a two-step authentication code.
- The PC may submit 340B ceiling prices, so please ensure you have the appropriate level personnel listed.
- If you have multiple labeler codes, be prepared to submit pricing for each. Each labeler code has an AO and PC listed, so manufacturers should verify whether or not the same person is responsible for all or some of its labeler codes as AO and PC.
- Visit the 340B OPAIS Educational Resource web page and sign up for program updates. Review the Manufacturer Compliance FAQs here.
- Ensure that all internal calculations are completed in a timely manner so that the authorized users are able to submit the data into the system. HRSA requests that manufacturers report 340B pricing data (instrument file) for all NDCs within a two-week submission period beginning approximately 45 days after the end of the previous quarter. These data are compared with the HRSA data on file (AMP and URA from CMS), PS (package size), and CSP (case package size) from First Data Bank (FDB).
- Failure to reconcile by the end of the manufacturer upload period will result in the 340B pricing component taking HRSA data points.
- In the case of new drug prices, the manufacturer should submit WAC (at the unit level) as a replacement for AMP and the required rebate percentage as the URA (as a value). The submitted WAC is as of the first day of the next quarter and is used to calculate the estimated ceiling price in accordance with the CMP Final Rule and is the price effective for the next quarter. The manufacturer must indicate in the notes section if the NDC is a new drug price estimate.
- Ensure internal procedures and personnel are in place to address pricing inquiries from covered entities.
- Additional OPAIS Pricing navigation/user tips include:
- When reconciling a difference from CMS data for AMP or URA, provide a detailed reason for the difference and note whether the information has been updated/restated in DDR or with CMS separately.
- Package size should be provided in the same units as the AMP is reported to CMS.
- Case package size should reflect the number of salable units in a shipping container that an individual purchaser would receive (what a covered entity would purchase rather than what a wholesaler would receive from a manufacturer).
- If NDCs are sold or transferred, the selling and acquiring manufacturer should establish a relationship for submitting pricing.
- Once the “submit finalized pricing” button is selected, the submission cannot be returned to the manufacturer for editing.
- If a few lines of the text file have errors, manual entry for those products may be easier to submit than trying to re-upload the entire file.
- If accurate and updated information is provided for the quarterly submission to CMS, there should be less work needed for manufacturers to reconcile in OPAIS.
The 340B CMP Final Rule and the implementation of the new secure pricing component of the 340B OPAIS have significant impact, including CMPs for manufacturers that knowingly and intentionally overcharge covered entities.
In addition to continuing to monitor 340B Program developments, manufacturers should ensure that appropriate staff understand program requirements and are diligent in documenting and following updated operational procedures and business assumptions. Many resources are available to assist in this process, including the HRSA 340B website and the 340B Prime Vendor Program, including Apexus Answers.